D. Boral Capital Forecasts Strong Price Appreciation for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price boosted by research analysts at D. Boral Capital from $2.00 to $3.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. D. Boral Capital’s price target suggests a potential upside of 60.86% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Lineage Cell Therapeutics in a research note on Friday. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $5.00.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX stock traded up $0.03 on Friday, reaching $1.87. 1,244,653 shares of the company were exchanged, compared to its average volume of 1,121,219. Lineage Cell Therapeutics has a 1 year low of $0.37 and a 1 year high of $2.09. The business has a 50-day moving average price of $1.72 and a 200 day moving average price of $1.64. The company has a market cap of $429.57 million, a price-to-earnings ratio of -6.43 and a beta of 1.74.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative net margin of 625.53% and a negative return on equity of 72.02%. The firm had revenue of $6.61 million for the quarter, compared to analyst estimates of $1.96 million. As a group, equities analysts anticipate that Lineage Cell Therapeutics will post -0.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Royal Bank of Canada raised its position in Lineage Cell Therapeutics by 1,578.9% during the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock worth $237,000 after acquiring an additional 497,168 shares during the last quarter. Rhumbline Advisers increased its stake in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after buying an additional 18,092 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $368,000. Catalyst Funds Management Pty Ltd acquired a new position in Lineage Cell Therapeutics in the second quarter valued at about $75,000. Finally, XTX Topco Ltd increased its holdings in shares of Lineage Cell Therapeutics by 117.8% during the second quarter. XTX Topco Ltd now owns 94,054 shares of the company’s stock worth $85,000 after buying an additional 50,876 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.